Heart Panel

Plavix@ (clopidogrel bisulfate)
• Plavix is used to prevent blood clots after a recent heart attack or stroke
• 25% of of patients are bad metabolizers of the drug.
• A number of genes are involved with this activation process and individuals with a particular genetic variant are unable to convert clopidogrel into its active form.
• This test will determine if the tested party has the gene to block the medicine for working properly.
Beta Blockers
• Beta blockers are often used to prevent heart attacks.
• Genotyping allows drug selection and dosing to individuals based on their gene composition for drug metabolism.
• This will provide proper selection and dosing of the most effective beta blockers, while minimizing failures or ADR.
Warfarin Resistance
• This test helps doctors determine proper dosage of warfarin.
• Treatment management remains difficult without this test as a result of the variable patient response to dosing
• High metabolizers of the drug have a risk for a serious bleeding event.
• This test helps doctors determine proper dosage of warfarin.
Anticoagulants and Antiplatelet Agents
• Anticoagulants are drugs that are given to prevent your blood from clotting or prevent existing clots from getting larger.
• With DNA testing the dosage of these medicines are a guessing game of prescribe and follow-up.
• Over dosing can cause internal bleeding and death.
• Having two copies of ApoE2 increases the risk of premature vascular disease.
• ApoE provides the instructions for making protein which is responsible for transporting cholesterol through the bloodstream.
• Knowing which APO E alleles you have can help you understand the risk of heart disease.
Factor II
• This test allows the doctor to understand the risk of venous thrombosis in their patients.
• Patients with a previous or current thrombotic events that possess the G20210A gene polymorphism are increased risk for recurrence.
Factor V Leiden + Factor VII
• The risk of thrombosis is substantially increased in patients with multiple genetic risk genes.
• This should be completed with the other factor panels to determine the complete genetic risk factor for the patient.
• This is the test for the likelyhood a treated pateint can develop clots caused by medcine supplied treating the patient.
• The MTHFR gene instructs the making an enzyme called methylenetetrahydrofolate reductase.
• Hyperhomocysteinemia indicates an increased risk for coronary artery disease, and an increase risk of stroke.
• Elevated homosysteine levels double the risk of developing venous thromboembolism.